Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
G.R. Hughes.
The antiphospholipid syndrome: Ten years on.
Lancet., (1993), 342 pp. 341-344
[2]
M.L. Bertolaccini, O. Amengual, L. Andreoli, T. Atsumi, C.B. Chighizola, R. Forastiero, et al.
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.
Autoimmun Rev., (2014), 13 pp. 917
[3]
Erkan D, Ortel T. Diagnosis of antiphospholipid síndrome. Pisetsky DS, ed. UpToDate. Waltham, MA: UpToDate Inc. Disponible en: https://www.uptodate.com/contents/diagnosis-of-antiphospholipid- syndrome (acceso el 1 de julio 2019).
[4]
G.R. De Jesus, N. Agmon-Levin, C.A. Andrade, L. Andreoli, C.B. Chighizola, T.F. Porter, et al.
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome.
Autoimmun Rev., (2014), 13 pp. 795-813
[5]
R.A. Asherson, M.A. Khamashta, J. Ordi-Ros, R.H. Derksen, S.J. Machin, J. Barquinero, et al.
The “primary” antiphospholipid syndrome: major clinical and serological features.
Medicine (Baltimore)., (1989), 68 pp. 366-374
[6]
S. Negrini, F. Pappalardo, G. Murdaca, F. Indiveri, F. Puppo.
The antiphospholipid syndrome: from pathophysiology to treatment.
Clin Exp Med., (2017), 17 pp. 257-267
[7]
C. Sobrino Grande, L. Villalobos Sánchez, M. Valero Expósito, M.J. García Villanueva.
Síndrome antifosfolípido.
Medicine., (2017), 12 pp. 1551-1559
[8]
V.M. Abrahams, L.W. Chamley, J.E. Salmon.
Antiphospholipid syndrome and pregnancy: pathogenesis to translation.
Arthritis Rheumatol., (2017), 69 pp. 1710-1721
[9]
K. Oku, H. Nakamura, M. Kono, K. Ohmura, M. Kato, T. Bohgaki, et al.
Complement and thrombosis in the antiphospholipid syndrome.
Autoimmun Rev., (2016), 15 pp. 1001-1004
[10]
M.M. Abreu, A. Danowski, D.G. Wahl, M.C. Amigo, M. Tektonidou, M.S. Pacheco, et al.
The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.
Autoimmun Rev., (2015), 14 pp. 401-414
[11]
M.L. Bertolaccini, O. Amengual, B. Artim-Eser, et al.
Clinical and prognostic significance of non-criteria antiphospholipid antibody tests.
En: Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights., Springer International Publ., pp. 171
[12]
M.S. Sater, R.R. Finan, F.M. Abu-Hijleh, T.M. Abu-Hijleh, W.Y. Almawi.
Anti-phosphatidylserine, anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks.
Eur J Obstet Gynecol Reprod Biol., (2012), 163 pp. 170-174
[13]
R.M. Silver, C.B. Parker, U.M. Reddy, R. Goldenberg, D. Coustan, D.J. Dudley, et al.
Antiphospholipid antibodies in stillbirth.
Obstet Gynecol., (2013), 122 pp. 641-657
[14]
K. Abou-Nassar, M. Carrier, T. Ramsay, M.A. Rodger.
The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis.
Thromb Res., (2011), 128 pp. 77-85
[15]
L.B. Helgadottir, F.E. Skjeldestad, A.F. Jacobsen, P.M. Sandset, E.M. Jacobsen.
The association of antiphospholipid antibodies with intrauterine fetal death: Acase-control study.
Thromb Res., (2012), 130 pp. 32-37
[16]
R. Cáliz Cáliz, P. del Campo Fontecha, M. Galindo Izquierdo, F.J. López Longo, M.A. Martínez Zamora, A. Santamaría Ortiz, et al.
Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento.
Reumatol Clin., (2019),
[17]
S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, R. Cervera, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost., (2006), 4 pp. 295-306
[18]
R.T. Urbanus, B. Siegerink, M. Roest, F.R. Rosendaal, P.G. de Groot, A. Algra.
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study.
Lancet Neurol., (2009), 8 pp. 998-1005
[19]
I.A. Naess, S.C. Christiansen, S.C. Cannegieter, F.R. Rosendaal, J. Hammerstroem.
A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).
J Thromb Haemost., (2006), 4 pp. 44-49
[20]
A. Ruffatti, M. Tonello, A. Cavazzana, P. Bagatella, V. Pengo.
Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy.
Thromb Res., (2009), 123 pp. 482-487
[21]
B. Giannakopoulos, S.A. Krilis.
The pathogenesis of the antiphospholipid syndrome.
N Engl J Med., (2013), 368 pp. 1033-1044
[22]
M. Galli, D. Luciani, G. Bertolini, T. Barbui.
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.
Blood., (2003), 101 pp. 1827-1832
[23]
S. Zuily, B. de Laat, S. Mohamed, H. Kelchtermans, Z. Shums, R. Albesa, et al.
Validity of the global anti-phospholipid síndrome score to predict thrombosis: a prospective multicentre cohort study.
Rheumatology., (2015), 54 pp. 2071-2075
[24]
C. Wang, X. Guan.
Laboratory diagnosis of antiphospholipid syndrome.
Frontiers in Laboratory Medicine., (2018), 2 pp. 97-101
[25]
D. Erkan, C.L. Aguiar, D. Andrade, H. Cohen.
14th International Congress on Anti-phospholipid Antibodies: task force report onantiphospholipid syndrome treatment trends.
Autoimmun Rev., (2014), 13 pp. 685-696
[26]
L. Arnaud, A. Mathian, A. Ruffatti, D. Erkan, M. Tektonidou, R. Cervera, et al.
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.
Autoimmun Rev., (2014), 13 pp. 281-291
[27]
L. Arnaud, A. Mathian, H. Devilliers, A. Ruffatti, M. Tektonidou, R. Forastiero, et al.
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.
Autoimmun Rev., (2015), 14 pp. 192-200
[28]
Erkan D, MD, Ortel T. Treatment of antiphospholipid síndrome. Pisetsky DS, ed. UpToDate. Waltham, MA: UpToDate Inc. Disponible en: https://www.uptodate.com/contents/treatment-of-antiphospholipid- syndrome (acceso el 1 de julio 2019).
[29]
V. Pengo, G. Denas, G. Zoppellaro, S. Padayattil Jose, A. Hoxha, A. Ruffatti, L. Andreoli, et al.
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Blood., (2018), 32 pp. 1365-1371
